Sunshine Biopharma Amends Articles Of Incorporation To Allow For Reverse Stock Split Of Up To 1-For-20; Board Of Directors Has Discretion To Effect The Split

On September 15, 2026, the Company received written consent in lieu of a meeting of stockholders from Dr. Steve N. Slilaty, our Chief Executive Officer, the holder of approximately 97% of the total voting power of the stockholders of the Company to approve amending our articles of incorporation to effect a reverse stock split of our common stock by a ratio of up to 1-for-20, with the Board of Directors having the discretion as to whether or not the reverse split is to be effected, and with the exact ratio of any reverse split to be set at a whole number up to 1-for-20 as determined by the Board in its discretion.